Shreehas Tambe is CEO and Managing Director of Biocon Limited, a biopharmaceutical company. GLP-1 therapies have changed the treatment of type 2 diabetes – but the debate is dominated by promises of weight loss and cost issues. With the first patent expirations, generics and biosimilar insulins are coming into focus as an opportunity for affordable … Continue reading How generics and biosimilars make diabetes care affordable
